Daniel Douglas Von Hoff MD
Professor of Medicine, University Ariz College of Medicine
Join to view full profile
13400 E Shea BlvdScottsdale, AZ 85259
Phone+1 480-301-8000
Fax+1 480-323-1359
Dr. Von Hoff is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Internal Medicine, 1973 - 1975
Columbia University Vagelos College of Physicians and SurgeonsClass of 1973
National Institutes of Health Clinical CenterFellowship, Medical Oncology
Certifications & Licensure
CA State Medical License 2014 - 2028
TX State Medical License 1980 - 2028
AZ State Medical License 1999 - 2027
MD State Medical License 1977 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow (FASCO) American Society of Clinical Oncologists, 2007
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- Pancreatic Cancer Detection Consortium Start of enrollment: 2023 Mar 15
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 10 citationsTumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-World Data.Celine Yeh, Mengxi Zhou, Keith Sigel, Gayle Jameson, Ruth White
The Oncologist. 2023-02-08 - 10 citationsPharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.Russell Moser, James Annis, Olga Nikolova, Cliff Whatcott, Kay Gurley
Cancer Research. 2022-09-16 - 39 citationsA phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.Nebojsa Skorupan, Mehwish I Ahmad, Seth M Steinberg, Jane B Trepel, Derek Cridebring
Future Oncology. 2022-06-01
Press Mentions
What Is a ‘Tolerable’ Dose? AACR-Industry Roundtable 2025 Examines Dose OptimizationDecember 5th, 2025- City of Hope Research Spotlight, February/March 2025May 15th, 2025
Grant Support
- Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic CancerBECKMAN RESEARCH INSTITUTE/CITY OF HOPE2017–2028
- Methods In Clinical Cancer Research WorkshopNational Cancer Institute2009–2011
- Aurora Kinases As Therapeutic Targets In Pancreatic CancerNational Cancer Institute2007–2010
- Targets To Therapeutics In Pancreatic CancerNational Cancer Institute2005–2009
- Pancreas Cancer Biospecimens RepositoryNational Cancer Institute2005–2009
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: